malaria
common
parasit
diseas
world
half
world
popul
expos
diseas
caus
protozoan
plasmodium
transmit
femal
anophel
mosquito
clinic
phase
human
infect
correspond
invas
red
blood
cell
rbc
form
parasit
follow
first
phase
develop
liver
inject
anophel
rbc
parasit
develop
intern
digest
host
cell
content
differenti
schizont
contain
multipl
invad
new
rbc
two
form
malaria
particularli
sever
prognost
cerebr
malaria
mainli
young
children
due
sequestr
matur
parasit
brain
consequ
adher
parasit
rbc
endothelium
cerebr
capillari
vessel
malaria
occur
pregnant
women
due
mass
sequestr
infect
erythrocyt
placenta
among
five
speci
current
recogn
infect
human
plasmodium
falciparum
deadli
other
p
vivax
p
malaria
p
oval
p
knowlesi
among
billion
peopl
expos
across
countri
malaria
caus
million
clinic
case
per
year
even
though
falciparum
malaria
rife
nearli
tropic
subtrop
area
world
africa
current
worst
affect
accumul
statist
total
malaria
clinic
episod
caus
total
number
death
direct
child
mortal
one
child
die
malaria
everi
indirect
child
mortal
sever
prognosi
mother
children
infect
occur
first
pregnanc
fatal
outcom
malaria
caus
mani
sequela
surviv
patient
mainli
young
children
disabl
adult
infecti
episod
malaria
burden
express
dali
disabilityadjust
life
year
rank
fourth
diseas
lowincom
countri
behind
lower
respiratori
infect
diarrheal
diseas
aid
heavi
consequ
malaria
includ
anemia
increas
child
mortal
markedli
reduc
power
product
adult
deficit
intellectu
develop
consequ
futur
evolut
develop
product
concern
area
lower
incom
countri
malaria
repres
gross
domest
product
gdp
per
capita
result
malaria
poverti
imped
factor
develop
countri
affect
diseas
face
challeng
intern
financ
increas
global
fund
fight
aid
tuberculosi
malaria
gftam
support
commit
us
million
malaria
howev
among
countri
support
strategi
sinc
repres
million
peopl
live
stabl
transmiss
condit
receiv
estim
combin
annual
support
lower
us
per
capita
enough
fight
effici
malaria
vaccin
would
theoret
repres
best
way
settl
problem
malaria
remain
far
despit
larg
amount
money
devot
research
area
last
year
number
paper
publish
even
protect
malaria
appear
possibl
base
sum
observ
collect
intern
organ
program
appropri
technolog
health
path
malaria
vaccin
initi
mvi
european
malaria
vaccin
initi
emvi
unit
state
aid
usaid
involv
feasibl
studi
concern
aspect
malaria
vaccin
howev
current
acut
debat
concern
acquisit
antimalari
immun
optim
design
malaria
vaccin
effici
fight
malaria
mainli
includ
control
mosquito
vector
indoor
residu
spray
protect
bite
insecticid
treat
net
chemoprophylaxi
chemotherapi
state
infect
gave
promis
result
mainli
low
transmiss
rate
area
fail
erad
malaria
region
intens
transmiss
even
progress
notic
sever
countri
howev
cost
intervent
high
repres
domest
expens
lowincom
countri
must
support
larg
part
intern
intervent
multilater
initi
malaria
roll
back
malaria
project
gftam
medicin
malaria
ventur
play
import
role
progress
observ
far
resist
spread
anophel
plasmodium
disprov
efficaci
global
fight
program
low
cost
insecticid
drug
interest
concern
popul
less
less
effici
insecticid
ddt
econom
interest
concurr
product
environment
problem
ad
mosquito
resist
problem
consequ
erad
program
abandon
extens
resist
chloroquin
low
cost
antimalari
resurg
malaria
occur
mani
part
world
sometim
devast
local
epidem
episod
sri
lanka
madagascar
high
prioriti
research
includ
develop
new
drug
treatment
malaria
develop
safe
molecul
mass
drug
administr
chemoprevent
develop
new
insecticid
indoor
residu
spray
longlast
insecticidetr
bed
net
develop
vaccin
high
transmissionblock
potenti
improv
access
treatment
poor
popul
cost
effici
drug
combin
malaria
chemotherapi
base
long
time
reduc
number
drug
mainli
quinin
chloroquin
antimetabolit
primaquin
occurr
resist
p
falciparum
sever
antimalari
provok
search
new
activ
molecul
variou
strategi
adopt
find
new
antimalari
result
industri
develop
mefloquin
halofantrin
artemisinin
deriv
sever
antibiot
spread
resist
cq
sulphadoxinepyrimethamin
decreas
suscept
parasit
new
drug
increas
interest
new
idea
concern
futur
malaria
chemotherapi
one
interest
suggest
use
alreadi
known
drug
artemisinin
combin
therapi
act
delay
occurr
resist
deciph
p
falciparum
genom
gave
access
thousand
potenti
new
target
gene
identifi
parasit
equival
orthologu
genom
sequenc
valid
new
target
long
way
away
sinc
requir
complex
genet
revers
manipul
perform
larg
scale
laboratori
worldwid
valid
target
design
specif
inhibitor
anoth
time
money
consum
step
sinc
requir
fine
knowledg
target
structur
design
specif
inhibitor
moreov
adequ
practic
method
test
larg
number
molecul
remain
limit
strategi
target
specif
parasit
probe
mani
method
use
search
new
activ
molecul
includ
ethnopharmacolog
medicin
chemistri
combinatori
chemistri
chemic
librari
screen
high
throughput
screen
drug
design
approach
sourc
numer
potenti
antimalari
molecul
success
enough
enter
queue
clinic
trial
invad
rbc
plasmodium
solv
multipl
problem
success
achiev
intraerythrocyt
cycl
keep
commun
exchang
tool
extracellular
compart
necessari
nutrient
provid
host
cell
get
necessari
space
within
rbc
welcom
siphon
amino
acid
necessari
growth
detoxifi
heme
liber
hemoglobin
hb
digest
form
hemozoin
also
call
malari
pigment
reorgan
surfac
rbc
order
escap
host
immun
defens
digest
hb
heme
detox
hemozoin
appear
critic
step
intraerythrocyt
cycl
provid
necessari
amino
acid
parasit
digest
hb
crucial
equilibrium
osmot
pressur
parasit
rbc
order
prevent
prematur
lysi
complet
cell
cycl
process
also
provid
space
parasit
increas
size
host
cell
hb
digest
parasit
produc
aminoacid
use
protein
synthesi
hb
digest
requir
special
structur
organ
parasit
soon
enter
ring
stage
modul
import
throughout
cell
cycl
sever
mechan
propos
captur
hb
parasit
recent
primari
process
call
big
gulp
occur
ring
stage
propos
origin
parasit
digest
vacuol
big
gulp
differ
classic
macropinocytosi
phagocytosi
actindepend
affect
treatment
cytochalasin
analysi
evolut
big
gulp
structur
suggest
origin
food
vacuol
contain
hemozoin
inde
big
gulp
goe
food
vacuol
cell
cycl
two
structur
observ
simultan
parasit
cytostom
structur
observ
parasit
shortli
invas
host
cell
cytostom
invagin
parasit
parasitophor
membran
current
activ
discuss
role
actin
format
structur
due
recent
evid
marker
associ
endosom
format
transport
eukaryot
cytostom
form
throughout
erythrocyt
cell
cycl
often
mani
found
one
parasit
subsequ
individu
small
vesicul
contain
hb
observ
numer
author
vesicul
appear
ring
stage
import
hb
uptak
becom
import
stage
transport
digest
vacuol
final
fuse
process
actin
digest
occur
structur
hemozoin
appear
even
fusion
digest
vacuol
inhibit
indic
acquir
necessari
enzym
factor
degrad
hb
biocrystal
hematin
cytostom
tube
produc
parasit
start
cytostom
elong
small
vesicl
describ
format
requir
actin
intervent
cytostom
tube
thought
import
role
hb
uptak
parasit
individu
digest
vesicl
propos
either
bud
termin
portion
tube
individu
differ
portion
tube
final
pigment
vesicl
propos
fuse
rapidli
produc
residu
vacuol
malari
pigment
suppos
sequestr
recent
observ
suggest
direct
fuse
cytostom
tube
food
vacuol
result
evolut
big
gulp
individu
vesicl
result
controversi
cytostom
tube
appear
erythrocyt
invas
global
volum
seem
small
limit
role
hb
uptak
parasit
phagotrophi
fourth
mean
parasit
captur
hb
mani
phagosom
appear
schizont
stage
unlik
typic
phagosom
found
eukaryot
format
actindepend
similar
mechan
big
gulp
four
mean
uptak
occur
differ
time
erythrocyt
cycl
big
gulp
might
take
part
hemoglobin
uptak
ring
stage
small
vesicul
deriv
cystostom
phagotrophi
might
promin
role
uptak
schizont
stage
doubt
remain
hypothesi
concern
role
cytostom
tube
uptak
might
import
propos
digest
hb
engulf
endocyt
structur
need
particular
condit
import
concern
action
mani
antimalari
four
aspart
proteas
falcipain
three
cysteic
proteas
plasmepsin
metalloproteas
falcilysin
dipeptidylpeptidas
probabl
aminopeptidas
involv
digest
hb
hb
primarili
attack
plasmepsin
falcipain
cleav
smaller
fragment
fragment
hydrolyz
falcilysin
small
peptid
final
aminoacid
liber
dipeptidylpeptidas
aminopeptidas
inhibitor
falcipain
plasmepsin
impair
kill
parasit
vitro
vivo
specif
strict
knockout
experi
sever
enzym
individu
combin
demonstr
normal
cultur
condit
p
falciparum
abl
acquir
import
part
aminoacid
necessari
environment
medium
isoleucin
absent
hb
entir
taken
parasit
rbc
outsid
compart
redund
way
hb
degrad
experi
also
show
proteolyt
enzym
overlap
role
hb
digest
reason
plasmepsin
repres
valuabl
drug
target
must
note
hb
degrad
strictli
necessari
parasit
surviv
restrict
use
produc
amino
acid
nutrit
also
make
room
maintain
osmot
pressur
requir
avoid
lysi
infect
rbc
enzym
involv
hb
digest
activ
ph
less
consequ
dv
acid
compart
parasit
repres
primari
interest
mechan
action
mani
schizontocid
antimalari
hemoglobin
degrad
free
heme
ferriprotoporphyrinix
fe
ii
ppix
releas
digest
vacuol
toxic
heme
parasit
demonstr
suppos
caus
disrupt
metabol
function
mean
peroxid
membran
inhibit
enzym
via
gener
oxid
free
radic
detoxif
heme
achiev
hemozoin
format
via
biominer
process
via
polymer
process
previous
envisag
first
iron
ii
fe
ii
ppix
oxid
iron
iii
fe
iii
ppix
hematin
molecul
fe
iii
ppix
link
dimer
reciproc
ironcarboxyl
bond
one
propion
side
chain
porphyrin
dimer
form
chain
link
hydrogen
bond
crystal
form
characterist
recent
defin
discuss
concern
mechan
action
antimalari
interact
hemozoin
format
mechan
biominer
low
solubl
hemozoin
thu
remov
biolog
environ
parasit
howev
doubt
remain
form
malaria
parasit
recent
result
shed
light
mechan
involv
among
three
propos
hypothes
explain
catalysi
nucleat
hematin
biocrystal
role
histidin
rich
protein
call
question
base
local
protein
capabl
knockout
parasit
form
pigment
fact
organ
lack
still
abl
produc
pigment
similar
hemozoin
clear
evid
format
hemozoin
occur
hydrophob
environ
within
surfac
lipid
plasmodium
organ
produc
hemozoin
experiment
work
confirm
hypothesi
activ
antimalari
clear
relat
interact
parasit
lipid
intervent
specif
enzym
biocrystal
hemozoin
larg
discuss
sinc
observ
heme
polymeras
activ
parasit
extract
difficulti
purifi
protein
show
activ
demonstr
biocrystal
could
occur
absenc
protein
discoveri
role
lipid
divert
interest
hypothesi
recent
gene
heme
detoxif
protein
hdp
character
recombin
protein
authent
protein
purifi
immunoprecipit
shown
interact
heme
high
affin
four
time
catalyz
effici
biocrystal
catalyt
activ
protein
optim
ph
lower
synthesi
protein
seem
export
infect
rbc
cytoplasm
intern
time
hb
parasit
knockout
experi
show
p
falciparum
hdp
locu
could
mutat
author
conclud
result
obtain
gene
certainli
critic
parasit
surviv
protein
appear
well
conserv
within
plasmodium
genu
fraction
total
hemozoin
relat
hdp
activ
still
discuss
resist
cq
first
report
columbia
thailand
earli
spread
worldwid
capit
observ
concern
cq
resist
done
krogstad
group
show
cqresist
parasit
accumul
significantli
less
cq
sensit
one
decreas
accumul
due
rapid
releas
cq
resist
parasit
time
acceler
efflux
slower
inhibit
calcium
channel
blocker
verapamil
dilthiazem
vinblastin
daunomycin
wherea
calcium
ionophor
activ
none
drug
affect
cq
accumul
efflux
sensit
parasit
revers
phenomenon
depend
acid
ph
digest
vacuol
author
point
similar
observ
revers
resist
multidrugresist
cancer
cell
affect
manner
verapamil
fact
time
two
main
research
method
develop
independ
search
origin
cq
resist
p
falciparum
rout
multidrug
resist
led
discoveri
character
gene
transport
propos
origin
cq
resist
first
gene
amplif
polymorphim
gene
field
observ
confirm
hypothesi
nevertheless
shown
amplif
polymorph
involv
possibl
associ
genet
factor
modul
suscept
sever
antimalari
mefloquin
halofantrin
quinin
artemisinin
field
studi
transfect
parasit
recent
studi
use
transfect
xenopu
leavi
oocyt
provid
direct
evid
transport
antimalari
gene
product
conduct
new
interpret
relat
cq
transport
rout
result
genet
cross
cqsuscept
cqresist
clone
p
falciparum
genet
analysi
progeni
result
show
resist
link
acceler
efflux
cq
outsid
parasit
suscept
verapamil
resist
level
independ
phenotyp
copi
number
locu
resist
situat
chromosom
chromosom
found
start
result
wellem
et
al
complet
dissect
area
suspect
contain
chr
final
select
area
contain
gene
analyz
first
gene
postul
origin
cq
resist
confirm
mani
epidemiolog
studi
transfect
experi
discoveri
gene
pfcrt
code
protein
local
digest
vacuol
membran
carri
specif
mutat
cqresist
parasit
provid
one
key
capit
cq
resist
role
pfcrt
protein
mutat
cq
resist
rapidli
confirm
field
isol
mutat
pfcrt
describ
cqresist
p
falciparum
isol
cqresist
isol
share
common
mutat
posit
mutat
never
present
gene
resist
parasit
alon
least
point
mutat
found
two
major
haplotyp
found
sever
studi
show
level
cq
resist
associ
haplotyp
mechan
pfcrt
confer
resist
chloroquin
still
discuss
first
aspect
concern
natur
protein
whether
pfcrt
postul
possess
ten
transmembran
helic
consid
member
drugmetabolit
transport
famili
protein
author
discuss
channel
natur
protein
suggest
chang
charg
lysin
uncharg
threonin
affect
electrostat
interact
diproton
cq
mutat
form
absenc
electrostat
interact
allow
drug
cross
channel
result
efflux
drug
dv
note
reduc
accumul
partial
revers
verapamil
lipophil
compound
experi
shown
mutat
factor
modul
action
pfcrt
cooper
group
demonstr
mutat
transmembran
domain
alter
suscept
cq
quinin
quinidin
photoaffin
label
pfcrt
novel
perfluorophenylazido
cq
provid
new
inform
concern
interact
drug
protein
mutat
confer
cq
resist
increas
cqassoci
h
leak
parasit
digest
vacuol
recent
observ
shown
pfcrt
may
exert
protect
role
even
erythrocyt
stage
hemoglobin
digest
product
pigment
activ
ring
late
schizont
hand
keep
mind
cq
resist
biolog
cost
parasit
geograph
area
abandon
cq
use
result
resurg
suscept
phenotyp
pfcrt
consid
author
metabolitedrug
transport
expect
mutat
protein
modifi
physiolog
parasit
comparison
transcriptom
clone
carri
wild
type
pfcrt
clone
carri
singl
mutat
gene
show
mrna
level
gene
modifi
compar
wild
type
parent
upregul
gene
involv
invas
cell
growth
develop
signal
transduct
transport
activ
gene
encod
protein
involv
transport
andor
regul
cytoplasm
compartment
ph
current
knowledg
favor
intervent
one
gene
modul
cq
resist
even
pfcrt
appear
play
main
role
seem
difficult
simultan
target
sever
gene
overcom
cq
resist
especi
factor
remain
precis
identifi
howev
revers
q
resist
verapamil
relat
drug
common
characterist
cqresist
strain
p
falciparum
open
way
futur
therapeut
synthesi
ferrocenyl
sugar
exemplifi
antimalari
activ
report
wherea
organ
parent
compound
ellagitannin
deriv
display
antimalari
activ
diferrocenyl
glucosid
show
inhibitori
activ
similar
quinin
cqsuscept
strain
seri
ferrocenyl
chalcon
exemplifi
two
compound
evalu
vitro
antimalari
activ
cqresist
strain
disappoint
low
activ
micromolar
rang
report
result
show
locat
ferrocen
influenc
eas
oxid
iron
ii
polar
carbonyl
linkag
paramet
found
influenc
antiplasmodi
activ
better
antimalari
activ
obtain
ferrocen
moieti
adjac
carbonyl
group
order
exploit
cation
redox
behavior
methylen
blue
antimalari
agent
new
ferrocen
benzimidazolium
conjug
design
synthes
test
p
falciparum
malari
parasit
strain
compound
thiophen
moieti
r
group
show
similar
cq
artemet
unfortun
data
vivo
activ
avail
introduct
ferrocen
core
chemic
structur
artemesinin
enhanc
antimalari
activ
compar
artemesinin
dihydroartemisinin
alon
whatev
chosen
linker
ether
ester
amin
fragment
improv
antimalari
activ
note
therefor
conclud
incorpor
ferrocen
moieti
artemesinin
skeleton
improv
activ
similar
strategi
base
coupl
activ
fragment
led
design
two
new
seri
atovaquon
conjug
compound
test
toxoplasma
gondii
p
falciparum
lipophil
deriv
aliphat
chain
carbon
atom
activ
atovaquoneresist
ato
gondii
clone
antimalari
activ
micromolar
rang
report
cqsuscept
strain
cqresist
strain
wherea
deriv
atovaquon
report
interfer
oxid
dihydroorot
data
deriv
avail
exploit
structurebas
strategi
quinuclidinyl
piperidinyl
side
chain
quinin
qn
mefloquin
mf
respect
substitut
ferrocen
moieti
maintain
basic
amino
group
vitro
lower
activ
parent
compound
report
acid
aqueou
solut
ferrocenyl
analog
seem
unstabl
lead
format
presum
inact
carbenium
inspir
bioorganometal
approach
two
seri
ferrocenyl
pyrrolo
quinoxalin
design
prepar
deriv
test
vitro
three
differ
strain
p
falciparum
pfb
best
result
comparison
cq
observ
first
seri
bi
piperazin
linker
compound
test
abil
inhibit
format
one
case
deriv
interfer
hemozoin
format
suggest
differ
mechan
action
compar
classic
famili
toxic
high
develop
stop
quinolon
fluoroquinolon
wide
use
bacteria
mycobacteria
recent
shown
similarli
gondii
pharmalog
concentr
ciprofloxacin
act
p
falciparum
among
fluoro
quinolon
activ
bacteria
test
p
falciparum
strain
none
show
activ
better
activ
prove
grepafloxacin
gatifloxacin
moxifloxacin
moreov
sever
quinolon
prove
activ
vitro
cqsuscept
cqresist
p
falciparum
strain
curious
although
hundr
analog
ciprofloxacin
synthes
relationship
analyz
bioorganometal
strategi
previous
envisag
therefor
new
ciprofloxacin
deriv
bear
ferrocenyl
substitu
posit
n
c
quinolon
ring
design
lead
compound
bear
ferrocenyl
moieti
posit
n
identifi
deriv
activ
ciprofloxacin
doxycyclin
activ
remark
constant
regardless
level
resist
cq
strain
contrari
antibiot
delayeddeath
effect
note
isobologram
analysi
show
compound
exert
antagonist
effect
main
quinolinecontain
antimalari
vitro
result
confirm
vivo
check
bioavail
molecul
potenti
interest
new
antimalari
idea
mind
ie
limit
number
reaction
step
reduc
cost
product
direct
condens
ferrocenylmethyl
fem
moieti
endocycl
nitrogen
cq
afford
quaternari
ammonium
salt
nevertheless
modif
cq
abolish
activ
parent
molecul
cqresist
suscept
p
falciparum
strain
hypothes
charg
speci
abl
cross
membran
stack
ferriprotoporphyrin
ring
due
unfavor
electrostat
interact
andor
steric
hindranc
laboratori
strain
low
antimalari
activ
also
observ
compound
quinolin
cycl
substitut
posit
fem
bulki
ferrocenyl
group
steric
hinder
stack
interact
quinolin
ring
heme
andor
fem
modifi
charg
densiti
distribut
quinolin
cycl
particular
attent
devot
studi
impact
introduct
ferrocenyl
moieti
later
side
chain
cq
implic
dv
target
moreov
length
side
chain
distanc
two
exocycl
nitrogen
atom
may
affect
resist
p
falciparum
shorter
two
three
carbon
atom
longer
side
chain
carbon
atom
cq
activ
cqresist
p
falciparum
suggest
molecul
space
less
suit
bind
put
cq
transport
therefor
less
effici
extrud
food
vacuol
seri
cq
analog
character
presenc
ferrocenyl
group
attach
termin
basic
nitrogen
atom
cq
later
chain
synthes
test
wherea
analog
found
activ
cq
present
optim
activ
compar
other
compound
benzylcarbamoyl
substitu
r
chain
length
n
made
signific
differ
efficaci
cqsuscept
strain
decreas
efficaci
increas
length
methylen
spacer
note
cqresist
strain
compound
fem
group
end
side
chain
show
activ
decreas
rapidli
level
cqresist
among
p
falciparum
clone
test
clearli
cross
resist
could
postul
emerg
quickli
signific
correl
either
liphophil
charact
vitro
inhibit
hemozoin
format
valu
among
cq
analog
bisferrocenyl
conjug
led
errat
activ
imposs
measur
precis
valu
mainli
due
stabil
solubl
problem
cultur
medium
decreas
efficaci
observ
linear
branch
propylamino
chain
deriv
introduct
methyl
group
side
chain
favor
antimalari
activ
incorpor
ferrocen
core
later
side
chain
cq
two
amin
atom
led
design
ferroquin
fq
compound
shown
extrem
activ
cqsensit
cqresist
p
falciparum
fq
also
activ
deriv
vivo
consid
lead
compound
earli
detail
substitut
ferrocen
chiral
molecul
effort
made
design
achir
version
deriv
easiest
solut
move
second
substitu
cyclopentadienyl
cycl
achir
ferrocen
analog
much
activ
cq
exhibit
four
time
lower
activ
cqresist
strain
cq
sensit
strain
unfortun
vivo
data
avail
comparison
substitut
pattern
vs
search
quinolin
compound
evad
resist
problem
bisquinolin
found
promis
activ
cqresist
strain
ferrocenyl
bisquinolin
remain
effici
cqresist
strain
cq
although
compound
less
activ
cqsensit
strain
fq
synthesi
fq
simpl
quit
econom
render
fq
attract
develop
antimalari
drug
intend
use
area
concern
malaria
mostli
overlay
lowincom
countri
fq
obtain
start
commerci
avail
n
ferrocen
aldehyd
result
bond
format
twostep
sequenc
involv
metal
tertiobutyllithium
reaction
dmf
step
previous
studi
orient
two
substitu
cyclopentadienyl
unambigu
establish
aldehyd
convert
correspond
oxim
reduc
primari
amin
snar
reaction
amin
lead
desir
fq
fq
possess
planar
chiral
due
substitut
ferrocen
moieti
laboratori
synthet
method
develop
provid
separ
pure
enantiom
fq
approach
includ
biocatalyt
kinet
resolut
use
candida
rugosa
lipas
crl
key
step
enantioselect
acetyl
primari
hydroxi
group
lead
format
enantiomer
enrich
acet
remain
untransform
alcohol
isol
extrem
high
enantiomer
excess
ee
deacyl
enrich
acet
undertaken
mean
transesterif
process
catalyz
also
crl
reaction
provid
alcohol
high
enantiomer
puriti
ee
final
amino
alcohol
oxid
correspond
carboxaldehyd
engag
total
synthesi
fq
fq
note
semi
industri
scale
product
enantiom
obtain
start
racem
mixtur
prepar
chiral
chromatographi
activ
pure
enantiom
compar
racem
vitro
vivo
vitro
fq
enantiom
racem
found
equal
activ
cqsuscept
cqresist
p
falciparum
strain
vivo
enantiom
slightli
less
activ
racem
mixtur
cq
sensit
cq
resist
p
vinckei
vinckei
suggest
addit
synerget
effect
enantiom
moreov
fq
display
slightli
improv
cur
effect
fq
suggest
minor
differ
pharmokinet
properti
actual
vitro
cytotox
fq
fq
racem
appear
similar
cell
prolif
assay
critic
advers
affect
observ
phase
iia
clinic
trial
racem
enantiomer
mixtur
adopt
phase
iib
trial
associ
artesun
appar
partit
coeffici
log
cq
fq
measur
vacuolar
cytosol
ph
cytosol
ph
fq
lipophil
cq
wherea
differ
lipophil
slight
acid
dv
ph
threefold
term
basic
pk
two
drug
indic
fq
less
basic
cq
crystal
structur
fq
show
presenc
strong
intern
hydrogen
bond
anilino
group
tertiari
amino
n
togeth
electron
donat
properti
ferrocen
moieti
explain
decreas
pk
valu
absenc
special
transport
mechan
proven
see
text
vacuolar
accumul
ratio
var
could
predict
deriv
equat
use
calcul
log
valu
inde
diacid
base
log
function
acid
constant
pk
partit
coeffici
log
p
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
log
rm
calcul
log
p
log
wedg
rm
p
k
rm
rm
ph
wedg
rm
p
k
rm
rm
p
k
rm
rm
ph
end
document
use
formula
fq
would
expect
accumul
dv
much
cq
nevertheless
view
high
degre
variabl
method
pk
determin
mixtur
log
p
mixtur
error
could
includ
result
instead
calcul
log
valu
experiment
log
valu
also
exploit
var
calcul
follow
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
rm
var
log
log
dph
end
document
use
formula
fq
expect
accumul
cq
parasit
dv
howev
mathemat
model
could
subject
suspicion
bia
special
transport
mechan
could
exclud
even
strongli
suspect
inde
bind
free
heme
contribut
uptak
debat
real
concentr
fq
dv
compar
cq
still
open
experiment
data
urgent
need
valid
correct
mathemat
model
order
studi
structur
modif
fq
might
improv
antimalari
activ
sever
deriv
prepar
test
tertiari
amin
show
strong
antimalari
activ
especi
cqresist
strain
compound
two
tenfold
activ
cq
activ
fq
secondari
amin
c
also
possess
antimalari
activ
compar
fq
compound
exhibit
better
inhibitori
activ
strain
cq
structur
modif
allow
us
conclud
vitro
antimalari
activ
disturb
slight
modif
later
basic
side
chain
contrari
second
ferrocenyl
group
introduc
termin
nitrogen
atom
efficaci
compound
markedli
attenu
three
fq
deriv
rh
close
mimick
antimalari
drug
hydroxychloroquin
hcq
prepar
compound
differ
fq
side
chain
basic
nitrogen
atom
n
introduct
hydroxyl
group
provid
expect
reduct
cytotox
effect
compar
fq
moreov
metallocen
compound
inhibit
vitro
growth
p
falciparum
far
better
cq
best
result
obtain
r
ethyl
substitu
high
potent
antimalari
activ
compound
confirm
cambodian
field
isol
deriv
show
almost
level
activ
fq
expect
high
correl
r
fq
note
within
isol
test
suggest
two
compound
similar
mode
action
andor
uptak
parasit
oxid
metabol
tertiari
amin
like
cq
fq
occur
via
cytochrom
system
see
sect
detail
main
metabolit
gener
sidechain
dealkyl
lead
first
monodesalkyl
didesalkyl
deriv
similar
oxid
pathway
mediat
dealkyl
hydroxyferroquin
shown
fq
loss
ethanol
fragment
gener
secondari
amin
cleavag
gener
activ
monondesmethyl
dmfq
monondesethylfq
defq
respect
comparison
hcq
fq
tempt
suggest
clinic
use
hydroxyferroquin
format
activ
metabolit
may
occur
particip
global
activ
parent
product
moreov
new
class
bioorganometal
compound
exert
antivir
effect
select
toward
sarscov
infect
new
drug
may
offer
interest
altern
asia
sar
origin
malaria
remain
endem
chimer
ligand
approach
use
combin
properti
fq
thiosemicarbazon
tsc
inde
deriv
tsc
shown
potent
antimalari
activ
due
intrins
metal
eg
iron
chelat
properti
mechan
action
tsc
believ
result
gener
reactiv
oxygen
radic
contrari
presenc
ferrocen
moieti
within
later
chain
main
condit
requir
retain
strong
antimalari
activ
cqresist
p
falciparum
seen
coval
bind
activ
fragment
envisag
merg
amino
group
order
compar
contribut
fragment
analog
without
ferrocen
moieti
analog
without
moieti
also
synthes
chimera
tsc
fq
activ
deriv
four
differ
strain
p
falciparum
nevertheless
correspond
pure
organ
deriv
show
compar
potenc
contrari
previou
result
introduct
ferrocen
moieti
increas
antimalari
activ
notic
signific
differ
activ
ferrocenyl
compound
cqsuscept
cqresist
parasit
first
test
perform
vitro
p
falciparum
clone
acclim
isol
show
molecul
activ
equival
cq
cq
suscept
parasit
effici
cq
resist
parasit
similar
parasit
phenotyp
result
confirm
p
falciparum
clone
test
laboratori
preliminari
data
incit
us
explor
vivo
activ
fq
murin
malaria
model
subcutan
administr
fq
mice
infect
p
berghei
n
accord
fourday
blood
schizonticid
test
show
drug
valu
respect
cq
test
cur
test
show
efficaci
cq
also
limit
strain
vivo
test
unpublish
result
conduct
cur
test
fourday
blood
schizonticid
test
place
parasitemia
determin
day
mice
monitor
surviv
throughout
period
month
end
treatment
regular
control
verifi
mortal
relat
parasit
infect
experi
show
cur
dose
cq
p
berghei
n
strain
compar
report
condit
daili
dose
fq
cure
mice
similar
result
obtain
p
yoelii
ns
strain
cur
effect
cq
vs
mice
cure
fq
cure
cure
unpublish
result
experi
last
surviv
parasit
observ
immatur
rbc
reticulocyt
affin
p
berghei
p
yoelii
strain
immatur
rbc
well
known
get
round
problem
select
strain
p
vinckei
vinckei
invad
immatur
red
cell
condit
fq
cure
mice
equal
cqsuscept
cq
resist
p
vinckei
strain
dose
whilst
cq
cure
cq
sensit
line
cur
cq
resist
line
subtox
dose
one
promis
result
fq
equal
cur
given
subcutan
oral
indic
good
bioavail
parallel
extens
studi
p
falciparum
field
isol
gabon
seneg
cambodia
thailand
burmes
border
corrobor
efficaci
fq
parasit
whatev
resist
level
chloroquin
commonli
use
antimalari
mefloquin
quinin
halofantrin
artemisinin
deriv
cross
reactiv
observ
studi
cq
limit
demonstr
caus
differ
initi
parasitemia
among
isol
start
assay
independ
suscept
p
falciparum
phenotyp
variat
pfcrt
gene
respons
cq
resist
could
suspect
result
demonstr
molecular
level
cambodia
isol
extend
gene
current
involv
resist
aminoquinolin
antimalari
assay
done
select
plasmodium
clone
resist
fq
attempt
p
falciparum
fail
parasit
appear
day
pressur
unabl
develop
even
absenc
drug
medium
experi
conduct
vivo
murin
strain
p
yoelii
ns
result
multiresist
phenotyp
cq
mefloquin
fq
low
pathogen
strain
abl
develop
immatur
erythrocyt
maximum
parasitemia
mice
often
abl
cure
parasit
either
pressur
fq
absenc
drug
moreov
fq
resist
fix
genet
opposit
cq
resist
remov
drug
pressur
result
rapid
loss
resist
fq
alreadi
observ
artemisininresist
phenotyp
speci
strain
fq
pressur
cryopreserv
lost
resist
time
mous
inocul
two
condit
strain
remain
resist
cq
analysi
pycrt
show
mutat
compar
wild
type
line
critic
region
known
phenotyp
resist
result
pose
question
concern
potenti
mechan
resist
fq
plasmodium
also
origin
cq
resist
p
yoelii
recent
result
obtain
p
berghei
concern
transloc
gene
multidrug
resistanceassoci
protein
mrp
gene
chromosom
chromosom
chloroquin
resist
strain
rc
might
interest
lead
comprehens
mechan
involv
fq
resist
conclus
specif
pharmacolog
studi
show
fq
activ
strain
p
falciparum
current
resist
alreadi
use
antimalari
suscept
drug
depend
resist
phenotyp
alreadi
determin
experi
induc
resist
vitro
vivo
show
clearli
fit
cost
fq
resist
extrem
high
parasit
disprov
pathogen
nevertheless
one
may
keep
mind
resist
decreas
suscept
occur
antimalari
current
use
resist
could
emerg
fq
use
extens
futur
one
way
decreas
overcom
risk
use
fq
act
artesun
plan
phase
ii
clinic
assay
caution
taken
delay
occurr
resist
experiment
studi
remain
perform
select
clone
resist
fq
molecular
analysi
resist
might
provid
use
tool
monitor
risk
decreas
suscept
parasit
area
fq
use
human
cq
metabol
liver
mostli
oxid
via
cytochrom
enzym
system
lead
ndesethylchloroquin
didesethylchloroquin
success
dealkyl
side
chain
ultim
produc
comparison
cq
metabol
fq
examin
differ
vitro
anim
human
hepat
model
fq
also
metabol
via
major
dealkyl
pathway
monondesmethyl
fq
dmfq
din
ndesmethyl
fq
defq
minor
metabol
pathway
also
identifi
cytochrom
isoform
possibl
patient
isoform
mainli
involv
fq
oxid
interestingli
dmfq
remain
activ
fq
cqsuscept
strain
less
activ
fq
much
activ
chloroquin
cqresist
strain
metabolit
less
effect
fq
eight
tenfold
accord
valu
valu
show
would
effici
parasit
elimin
previous
dmfq
found
activ
fq
cqsuscept
strain
moder
cqresist
strain
defq
found
twofold
less
activ
ferroquin
two
metabolit
present
signific
concentr
blood
administr
fq
involv
global
antimalari
activ
fq
fq
exhibit
good
transepitheli
transport
monolay
intestin
epithelium
model
independ
ph
influenc
pgp
inhibitor
indic
good
oral
absorpt
confirm
experiment
result
alreadi
obtain
vivo
cur
assay
mice
use
oral
way
administr
moreov
drug
show
low
transfer
rate
blood
brain
barrier
vitro
model
transendotheli
transport
across
bovin
capillari
endotheli
cell
intraven
oral
administr
fq
show
extens
plasma
clearanc
larg
volum
distribut
larg
bioavail
plasma
concentr
high
rang
oral
administr
decreas
slowli
first
larg
distribut
observ
liver
brain
properti
close
alreadi
observ
cq
concern
erythrocyticplasma
distribut
three
model
test
rat
macaqu
monkey
human
converg
toward
high
level
accumul
fq
rbc
close
even
better
cq
test
rat
use
equival
dose
cq
caus
mortal
fq
caus
mortal
liver
lesser
extent
kidney
appear
two
main
target
organ
phase
iia
clinic
experi
confirm
good
toler
fq
lower
toxic
compar
cq
concern
embryotox
mutagen
fq
found
neg
frog
embryo
teratogenesi
assayxenopu
fetax
test
fq
enantiom
solubil
aqueou
solut
neg
ame
test
fq
respond
neg
micronucleu
vitro
vivo
assay
conduct
glp
standard
interestingli
kind
experi
cq
found
weakli
mutagen
genotox
conclus
fq
show
good
pharmacolog
profil
oral
absorpt
experiment
clinic
phase
assay
show
good
toler
fq
given
singl
dose
even
high
dosag
result
associ
activ
fq
first
metabolit
cqresist
p
falciparum
good
omen
futur
develop
fq
new
antimalari
confirm
current
pass
drug
clinic
phase
iib
first
chemic
synthesi
fq
laboratori
catalysi
lill
catalysi
solid
state
chemistri
umr
cnr
enscl
univers
scienc
technolog
lill
french
intern
patent
fq
first
test
fq
gabon
acclim
isol
p
falciparum
pascal
first
test
laboratori
clone
p
falciparum
rodent
malaria
vivo
daniel
first
contact
pharmaceut
industri
pierr
fabr
medica
pfm
ask
key
question
molecul
crystal
form
fq
obtainedsynthesi
fq
enantiom
c
biot
specif
pharmacolog
p
falciparum
rodent
malaria
vivo
daniel
dive
pfm
stop
activ
regard
malarianew
contact
anoth
pharmaceut
group
sanofi
aventi
fq
licens
sa
preliminari
develop
test
fq
field
isol
gabon
seneg
develop
fq
begin
phase
clinic
trial
first
human
first
administr
human
fq
intern
nonproprietari
patent
associ
fq
artemisinin
deriv
treat
malaria
sa
begin
phase
ii
clinic
compar
safeti
activ
studi
fqartesun
vs
amodiaquineartesun
african
adult
patient
fq
form
complex
hematin
solut
stoichiometri
log
moreov
presenc
fq
hematin
convert
dosedepend
inhibit
format
obtain
fq
wherea
cq
clearli
show
fq
strong
inhibitor
format
even
potent
cq
molecular
electrostat
potenti
mep
surfac
comput
level
theori
neutral
diproton
fq
cq
case
fq
cq
show
consider
similar
quinolin
area
sinc
part
molecul
thought
directli
interact
hematin
stack
interact
similar
mode
interact
activ
drug
fq
cq
hematin
suggest
howev
basic
lipophil
fq
significantli
differ
cq
lipophil
fq
cq
similar
proton
put
food
vacuol
ph
log
respect
differ
markedli
ph
log
respect
addit
pk
valu
fq
lower
pk
pk
cq
respect
free
base
fq
lipophil
cq
differ
may
explain
remark
activ
fq
compar
cq
inde
fq
may
target
lipid
site
hemozoin
format
effici
thu
power
inhibit
process
hemozoin
crystal
valid
disprov
theori
incub
parasit
fq
local
electron
microscop
autoradiographi
subcellular
fraction
envisag
avoid
use
radioact
materi
altern
method
use
electrondens
tracer
ruthenoquin
ruthenium
analog
fq
studi
uptak
ultrastructur
studi
treat
parasit
solidst
structur
neutral
fq
stabil
strong
intramolecular
hydrogen
bond
anilino
n
tertiari
amino
n
see
chap
solut
low
dielectr
constant
chloroform
lipid
environ
nmr
data
show
spatial
structur
fq
much
crystal
peculiar
shape
lead
increas
hydrophob
result
reject
bulki
ferrocenyl
moieti
toward
outsid
combin
spectroscop
structur
investig
reveal
extend
structur
fq
polar
solvent
chang
compact
conform
via
addit
intramolecular
hydrogen
bond
apolar
solvent
biot
et
al
role
noncoval
interact
antimalari
activ
question
end
analog
fqme
bear
methyl
group
instead
hydrogen
atom
anilino
n
synthes
compound
share
similar
physicochem
properti
fq
also
abl
inhibit
format
nevertheless
structur
modif
led
signific
reduct
activ
cqsuscept
cqresist
strain
presenc
hydrogen
bond
interact
later
side
chain
fq
contribut
antiplasmodi
activ
result
accord
previou
observ
fq
analog
hydroxyferroquin
b
includ
intramolecular
hbond
side
chain
shown
much
activ
molecul
lack
noncoval
interact
flipflop
hbond
open
conform
diproton
fq
fold
conform
neutral
fq
contribut
transport
water
hydrophob
membran
hydrophob
ferrocen
moieti
establish
favor
van
der
waal
interact
lipid
structur
involv
interfac
aqueou
content
dv
posit
fq
catalyt
site
hematin
preferenti
locat
fq
caus
inhibit
format
hemozoin
effici
cq
moreov
tight
bind
interact
fq
lipid
suggest
concentr
free
fq
water
decreas
fq
longer
substrat
efflux
transport
associ
cq
resist
biophys
biolog
approach
necessari
refin
hypothesi
current
develop
group
dv
parasit
free
heme
rapidli
convert
hematin
ie
iron
ii
oxid
iron
iii
process
electron
liber
promot
format
reactiv
oxygen
speci
ro
superoxid
anion
radic
hydrogen
peroxid
ro
caus
cellular
damag
hydrogen
peroxid
may
also
use
peroxid
degrad
heme
context
influenc
redox
behavior
fq
implic
antimalari
activ
question
specif
condit
acid
oxid
mimick
parasit
dv
fq
show
revers
oneelectron
redox
reaction
lead
format
ferriquinium
gener
hydroxyl
radic
kinet
relev
antimalari
activ
p
falciparum
cq
shown
induc
ro
product
astrogli
cell
via
signal
pathway
involv
nevertheless
rbc
devoid
nucleu
pathway
occur
addit
spin
trap
experi
demonstr
cq
abl
produc
radic
presenc
acid
ph
parasit
dv
contrari
use
experiment
condit
hydroxyl
radic
produc
fq
micromolar
concentr
wherea
product
weak
suffici
induc
signific
damag
fq
might
thu
strike
parasit
via
direct
inhibit
hemozoin
format
also
product
lethal
hydroxyl
radic
radic
known
particularli
aggress
toward
unsatur
fatti
acid
present
membran
phospholipid
promot
extens
chain
reaction
peroxid
product
alter
destruct
structur
influenc
heme
detoxif
process
could
result
complementari
harm
effect
parasit
experi
necessari
provid
answer
hypothes
conclus
activ
fq
due
one
rout
due
physicochem
properti
fq
could
specif
target
lipid
site
hemozoin
format
mechan
action
part
similar
cq
base
inhibit
hemozoin
format
upon
specif
acid
oxid
dv
condit
product
radic
oxygen
speci
ro
fq
suffici
promot
signific
damag
membran
parasit
dv
strong
activ
fq
cqresist
clone
isol
p
falciparum
suggest
fundament
differ
interact
resist
mechan
parasit
contribut
organometal
chemistri
develop
new
antimalari
promis
potenti
use
far
outcom
remain
limit
attempt
insert
organometal
moieti
alreadi
known
antimalari
base
idea
improv
activ
overcom
resist
parasit
parent
drug
result
remain
within
expect
except
cq
analog
serendipit
discoveri
fq
extens
studi
realiz
ferrocen
cq
conjug
provid
import
inform
role
ferrocen
core
antimalari
activ
posit
ferrocenyl
moieti
later
side
chain
cq
probe
precis
result
form
basi
new
idea
quinin
melfoquin
artemisinin
derivatis
influenc
ferrocenyl
moietyl
lipophil
realli
import
consid
antimalari
drug
cross
least
three
membran
reach
parasit
cytoplasm
five
six
membran
reach
inner
part
parasit
mitochondria
plastid
fine
analysi
fq
properti
led
underlin
possibl
specif
role
ferrocen
core
antimari
activ
via
product
hydroxyl
radic
presenc
specif
intramolecular
hydrogen
bond
molecul
seem
import
factor
activ
postul
weak
interact
confer
fq
potenc
interact
membran
lipid
specif
present
site
action
effici
insert
ferrocen
moieti
weak
base
cq
undoubtedli
increas
abil
target
parasit
digest
vacuol
possibl
enabl
drug
escap
resist
mechan
fq
phase
iib
clinic
trial
repres
first
organometal
antimalari
current
pipelin
promis
drug
moreov
pursuit
studi
regard
mechan
action
fq
possibl
mechan
resist
appear
promis
chemotherapi
malaria
also
basi
new
concept
drug
design
